Intima-Medial Thickness Guidance of Primary Prevention in Relatives of Patients With Early onSet … (NCT01330602) | Clinical Trial Compass
UnknownNot Applicable
Intima-Medial Thickness Guidance of Primary Prevention in Relatives of Patients With Early onSet Atherosclerosis
Singapore1,310 participantsStarted 2010-05
Plain-language summary
The primary objective of this study is, to instigate a reduction in atherosclerotic burden within the carotid arteries in the intervention group compared to the control group and to demonstrate parallel improvements in cardiovascular and overall health status relative to usual care
Who can participate
Age range40 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Have a first-degree relative (i.e. a mother, father, brother or sister) with premature (onset \<65 years of age) atherosclerosis. This includes coronary artery disease/acute myocardial infarction, non-haemorrhagic stroke and peripheral vascular disease.
* Are classified as "intermediate risk" of experiencing a cardiovascular event in the next 5 years as determined via the Framingham Risk Equation 7, 22
* Live within a geographically accessible area for follow-up (i.e. within a 40km radius of the study centre)
* Are living independently in the community or their own home
* Are able and willing to provide written informed consent to participate in the study (this includes the ability to understand and speak English fluently and that the patient is mentally competent)
Exclusion Criteria:
* Pre-existing atherosclerotic disease
* Have been diagnosed with Type 1 or Type 2 Diabetes Mellitus
* Have contraindications to the use of statin medications (includes pregnancy and breastfeeding)
* Unable to provide written informed consent to participate in this study
* Have a terminal malignancy requiring palliative care, or limited life expectancy or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial
* Participating in another clinical research trial